Surprisingly, the serum METCAM/MUC18 concentrations in the PIN patients were consistently higher than the prostate cancer patients, which could not be achieved by our previous traditional LFIA and ELISA test [18] and also the current PSA test (Figure 8). This evidence concerns the gene MCAM and prostate carcinoma.